Beclometasone hydrofluoroalkane inhalation - 3M
Alternative Names: Beclometasone dipropionate hydrofluoroalkane inhalation - 3M; Beclometasone HFA inhalation - 3M; Beclometasone pressurised metered-dose inhalation - 3M; Beclomethasone breath-activated inhalation - 3M; Beclomethasone dipropionate HFA - 3M; Beclomethasone dipropionate hydrofluoroalkane inhalation - 3M; Beclomethasone HFA inhalation - 3M; Beclomethasone hydrofluoroalkane inhalation - 3M; HFA-134a BDP; Hydrofluoroalkane-134a beclomethasone dipropionate; Junik; Nexxair®; Qvar; Qvar Autohaler; Qvar BAI; Qvar Easi-Breathe; Qvar MDI; Qvar RediHaler; Qvarspray; VentolairLatest Information Update: 05 Nov 2023
At a glance
- Originator 3M Pharmaceuticals
- Developer 3M Pharmaceuticals; Teva Branded Pharmaceutical Products R&D
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Chlorinated steroids; Corticosteroids; Pregnadienetriols; Small molecules; Vascular disorder therapies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Asthma
Most Recent Events
- 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
- 12 Apr 2021 No development reported - Phase-III for Asthma (In adolescents, In children) in Poland, Hungary, Germany (Inhalation)
- 12 Apr 2021 No development reported - Phase-III for Asthma (In children) in Poland, Ukraine, El Salvador, Croatia, Panama, Israel, Mexico (Inhalation)